Patent details

LUC00099 Product Name: Caplacizumab

Basic Information

Publication number:
LUC00099
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP121518930
Legal Status:
Inactive
Application number:
LUC00099
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1305
Marketing Authorization Type:
Marketing Authorization Date:
04/09/2018
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
06/02/2019
First Marketing Authorization date:
04/09/2018
Grant date:
27/12/2019
Activation date:
Publication date:
12/02/2019
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/05/2031
SPC Extension Expiration:
19/05/2031
Rejection date:
Withdrawal date:

Owner

From:
06/02/2019
 
 

Name:
Ablynx N.V.
Address:
Technologiepark 21, 9052 Ghent-Zwijnaarde, Belgium (BE)

Agent

Name:
Dennemeyer & Associates S.A.
From:
06/02/2019
Address:
PO Box 1502, L-1015, LUXEMBOURG, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2019/04
Publication date:
11/03/2019
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2020/01
Publication date:
13/01/2020
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
01/06/2026
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
22/02/2019 General Document 37
12/02/2019 Publication 1
22/02/2019 Incoming Correspondence (Post) 1
27/12/2019 Publication 1
27/12/2019 Certificate 1
06/02/2019 Application Form 5
12/02/2019 Outgoing Correspondence 1
06/02/2019 General Document 2
27/12/2019 Outgoing Correspondence 1
06/02/2019 General Document 3
22/02/2019 General Document 53
06/02/2019 General Document 1